Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiotherapy as a Treatment Option for Local Disease Control in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Zehnder M, Amarov B, Abrunhosa-Branquinho AN, Maiwald-Urosevic M, Mühleisen B, Saulite I, Anzengruber F, Imhof L, Navarini AA, Cozzio A, Dummer R, Dimitriou F, Guenova E. Zehnder M, et al. Among authors: anzengruber f. Dermatology. 2022;238(5):967-976. doi: 10.1159/000522053. Epub 2022 Feb 14. Dermatology. 2022. PMID: 35158362 Free article.
Blockade of programmed cell death protein 1 (PD-1) in Sézary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation.
Saulite I, Ignatova D, Chang YT, Fassnacht C, Dimitriou F, Varypataki E, Anzengruber F, Nägeli M, Cozzio A, Dummer R, Scarisbrick J, Pascolo S, Hoetzenecker W, Bobrowicz M, Guenova E. Saulite I, et al. Among authors: anzengruber f. Oncoimmunology. 2020 Mar 18;9(1):1738797. doi: 10.1080/2162402X.2020.1738797. eCollection 2020. Oncoimmunology. 2020. PMID: 32760603 Free PMC article.
Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in Sézary syndrome.
Anzengruber F, Ignatova D, Schlaepfer T, Chang YT, French LE, Pascolo S, Contassot E, Bobrowicz M, Hoetzenecker W, Guenova E. Anzengruber F, et al. Leuk Lymphoma. 2019 Aug;60(8):1899-1907. doi: 10.1080/10428194.2018.1564827. Epub 2019 Jan 14. Leuk Lymphoma. 2019. PMID: 30638415 Free article.
Successful intra-class switching among IL-17 antagonists: a multicentre, multinational, retrospective study.
Gasslitter I, Kirsten N, Augustin M, Torz K, Mrowietz U, Eyerich K, Puig L, Hoetzenecker W, Schütz-Bergmayr M, Weger W, Wolf P, Reider N, Ratzinger G, Papageorgiou K, Meier TO, Maul JT, Anzengruber F, Navarini AA. Gasslitter I, et al. Among authors: anzengruber f. Arch Dermatol Res. 2019 Jul;311(5):421-424. doi: 10.1007/s00403-019-01907-y. Epub 2019 Mar 16. Arch Dermatol Res. 2019. PMID: 30879102 Clinical Trial.
Observer-independent assessment of psoriasis-affected area using machine learning.
Meienberger N, Anzengruber F, Amruthalingam L, Christen R, Koller T, Maul JT, Pouly M, Djamei V, Navarini AA. Meienberger N, et al. Among authors: anzengruber f. J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1362-1368. doi: 10.1111/jdv.16002. Epub 2020 Jan 23. J Eur Acad Dermatol Venereol. 2020. PMID: 31594034 Free article.
Secukinumab for Acrodermatitis Continua of Hallopeau.
Muggli D, Maul JT, Anzengruber F, Fopp MW, Navarini AA. Muggli D, et al. Among authors: anzengruber f. JAMA Dermatol. 2017 Apr 1;153(4):336-337. doi: 10.1001/jamadermatol.2016.5059. JAMA Dermatol. 2017. PMID: 28122071 Free article. No abstract available.
53 results